Inotersen (Ionis TTRRx) for hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN) – first line

March 2017
Technology Description:

Inotersen is a new drug to treat hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), which is a rare disease caused by the abnormal build-up of proteins in the tissues of the body. Inotersen is delivered by injection under the skin. It stops a protein called transthyretin being made, and therefore stops it from building-up in body tissues.